Cracking The Code: Understanding Analyst Reviews For ResMed
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) has been analyzed by 9 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target has increased to $240.67. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. ResMed is a major player in the respiratory care device market, with strong financial performance and a focus on digital health.
October 25, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed has received a range of analyst ratings, with an average price target increase to $240.67. Analysts have adjusted their ratings and price targets, indicating a positive outlook. ResMed's strong financial performance and focus on digital health are key factors.
The increase in the average price target and the positive adjustments in analyst ratings suggest a favorable short-term outlook for ResMed. The company's strong financial performance and strategic focus on digital health further support this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100